Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -27.32% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.48 | N/A | -27.32% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern over the current financial performance. They highlighted the need for strategic adjustments moving forward.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting EPS expectations.
The earnings report indicates that Alnylam Pharmaceuticals is struggling to meet earnings expectations, which has led to a negative stock reaction of 4.1%. The lack of revenue data and guidance may raise concerns among investors about the company's future performance and strategic direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ROCKET COMPANIES CLA A
Nov 4, 2013